Medilink Therapeutics (suzhou) Co., Ltd.

This study tests a new medicine called YL201 against standard chemotherapy in 440 people with advanced esophageal cancer that has worsened after initial treatment. Participants are randomly assigned to receive either YL201 or a doctor-chosen chemo. The main goal is to see if YL20…

This study compares a new drug, YL202, with the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to previous treatments. About 440 adults aged 18 to 75 will take part. The main goals ar…

This phase 3 study tests a new drug, YL202, against standard treatments (like eribulin or capecitabine) in 376 people with advanced HR+/HER2- breast cancer that has not responded to at least one chemotherapy. The main goal is to see if YL202 can delay cancer growth or improve sur…